Impaired endothelial function and elevated levels of pentraxin 3 in early-onset preeclampsia

Acta Obstetricia et Gynecologica Scandinavica

Volumn 91, Issue 1, 2012, Pages 50-56

  Hamad, Rangeen Rafik ^a   Eriksson, Maria J ^a   Berg, Elisabeth ^a   Larsson, Anders ^b   Bremme, Katarina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti angiogenesis markers; endothelium; inflammatory; Pentraxin 3; preeclampsia

Indexed keywords

BIOLOGICAL MARKER; PENTRAXIN 3; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW MEDIATED DILATION; FOLLOW UP; GESTATIONAL AGE; HUMAN; OUTCOME ASSESSMENT; PREECLAMPSIA; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; SERUM AMYLOID P-COMPONENT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 83455219277     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2011.01238.x     Document Type: Article

References (48)

1. Lyall F, Greer IA,. The vascular endothelium in normal pregnancy and pre-eclampsia. Rev Reprod. 1996; 1: 107-16. (Pubitemid 126664713)
2. Stefanovic M, Vukomanovic P, Milosavlievic M, Kutlesic R, Popovic J, Tubic-Pavlovic A, et al,. Insulin resistance and C-reactive protein in preeclampsia. Bosn J Basic Med Sci. 2009; 9: 235-8.
3. Ouyang YQ, Li Sj, Zhang Q,. Plasma sFlt-1-to-PlGF ratio is correlated with inflammatory but not with oxidative stress in Chinese preeclamptic women. Arch Gynecol Obstet. 2009; 280: 91-7.
4. Newstead J, Von Dadelszen P, Magee LA,. Preeclampsia and future cardiovascular risk. Expert Rev Cardiovasc Ther. 2007; 5: 283-94. (Pubitemid 46488142)
5. Redman CW, Sargent IL,. Latest advances in understanding preeclampsia. Science. 2005; 308: 1592-4. (Pubitemid 40807500)
6. Poston L,. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep. 2006; 58 (Suppl): 69-74.
7. Garlanda C, Bottazzi B, Bastone A, Mantovani A,. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005; 23: 337-66. (Pubitemid 40563173)
8. Cetin I, Cozzi V, Pasqualini F,. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2006; 194: 1347-53.
9. Rovere-Querini P, Antonacci S, Dell'antonio G,. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol. 2006; 108: 148-55. (Pubitemid 44336858)
10. Cockell AP, Poston L,. Flow-mediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia. Hypertension. 1997; 30: 247-51. (Pubitemid 27329005)
11. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS, et al,. Association of maternal endothelial dysfunction with preeclampsia. J Am Med Assoc. 2001; 285: 1607-12. (Pubitemid 32240253)
12. Svedas E, Nisell H, Vanwijk MJ, Niklas Y, Kublickiene KR,. Endothelial dysfunction in uterine circulation in preeclampsia: can estrogens improve it? Am J Obstet Gynecol. 2002; 187: 1608-16. (Pubitemid 36026696)
13. Lopez-Jaramillo P, Arenas WD, Garcia RG, Rincon MY, Lopez M,. The role of the L- arginine-nitric oxide pathway in preeclampsia. Ther Adv Cardiovasc Dis. 2008; 2: 261-75.
14. Agatisa PK, Ness RB, Roberts JM, Constantino JP, Kuller LH, Mclaughlin MK, et al,. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol. 2004; 286: H1389-93. (Pubitemid 38381146)
15. Hamad RR, Eriksson MJ, Silveira A, Hamsten A, Bremme K,. Decreased flow-mediated dilation is present 1 year after a pre-eclamptic pregnancy. J Hypertens. 2007; 25: 2301-7. (Pubitemid 47537925)
16. Germain AM, Romanik MC, Guerra I,. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension. 2007; 49: 90-5. (Pubitemid 46360346)
17. Yeboah J, Crouse JR, Hus FC, Burke GL, Herrington DM,. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007; 115: 2390-7. (Pubitemid 46717961)
18. Garcia RG, Celedon J, Sierra-Laguadio J,. Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia. Am J Hypertens. 2007; 20: 98-103. (Pubitemid 46019850)
19. Takase B, Goto T, Hamabe A,. Flow-mediated dilation in brachial artery in the second half of pregnancy and prediction of pre-eclampsia. J Hum Hypertens. 2003; 17: 697-704. (Pubitemid 37265146)
20. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolades KH, et al,. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003; 361: 1511-7. (Pubitemid 36566342)
21. Ohkuchi A, Hirashima C, Matsubara S,. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res. 2007; 30: 151-9. (Pubitemid 46541789)
22. Maynard SE, Min JY, Merchan J,. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111: 649-58. (Pubitemid 36278583)
23. Koga K, Osuga Y, Yoshino O,. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol. Metab 2003; 88: 2348-51. (Pubitemid 36549917)
24. Hirashima C, Ohkuchi A, Aari F,. Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res. 2005; 28: 727-32. (Pubitemid 41723531)
25. Verlohren S, Galindo A, Schlembach D,. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010; 202: 161.e1-161.e11.
26. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE, et al,. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol. 2007; 197: 244 e1-8.
27. Rafik Hamad R, Larsson A, Pernow J, Bremme K, Eriksson MJ,. Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. J Hypertens. 2009; 27: 2257-64.
28. Davey DA, Macgillivary I,. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1988; 158: 892-8.
29. Stepan H, Unversucht A, Wessel N, Faber R,. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007; 49: 818-24. (Pubitemid 351664216)
30. Inoue K, Sugiyama A, Reid PC,. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007; 27: 161-7. (Pubitemid 46360394)
31. Latini R, Maggioni AP, Peri G,. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004; 110: 2349-54. (Pubitemid 39407338)
32. Peri G, Introna M, Corradi D,. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000; 102: 636-41. (Pubitemid 30640663)
33. Alberti L, Gilardini L, Zulian A,. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis. 2009; 202: 455-60.
34. Hawfield A, Freedman BI,. Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Ther Adv Cardiovasc Dis. 2009; 3: 65-73.
35. Castiglioni MT, Scavini M, Cavallin R,. Elevation of plasma levels of the long pentraxin 3 precedes preeclampsia in pregnant patients with type 1 diabetes. Autoimmunity. 2009; 42: 296-8.
36. Akolekar R, Casagrandi D, Livanos P, Tetteh A, Nicolaidies KH,. Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009; 29: 934-8.
37. Poon LC, Karagiannis G, Leal A, Romero XC, Nicolaides KH,. Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and bloodpressure at 11-13 weeks. Ultrasound Obstet Gynecol. 2009; 34: 497-502.
38. Galbiati S, Causarano V, Pinzani P,. Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy. Clin Chem Lab. Med; 48: 791-4.
39. Polliotti BM, Fry AQ, Saller DN, Mooney RA, Cox C, Miller RK, et al,. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol. 2003; 101: 1266-74. (Pubitemid 36694354)
40. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher FJ, North RA, et al,. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003; 188: 177-82. (Pubitemid 36135616)
41. Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y, et al,. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol. 2006; 194: 551-6. (Pubitemid 43183715)
42. Wikstrom AK, Larsson A, Eriksson UJ, Nash P, Norden-Lindeberg S, Olovsson M, et al,. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol. 2007; 109: 1368-74. (Pubitemid 46869876)
43. Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA,. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res. 2005; 57: 1R-7R. (Pubitemid 40593239)
44. Levine RJ, Maynard SE, Qian C,. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350: 672-83. (Pubitemid 38364626)
45. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ,. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation. 2010; 122: 478-87.
46. Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, Akahori Y, et al,. Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. Br J Obstet Gynaecol. 2010; 117: 314-20.
47. Cetin I, Cozzi V, Papageorghiou AT,. First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction. Acta Obstet Gynecol Scand. 2009; 88: 846-9.
48. Smith GC, Crossley, Aitken DA,. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007; 109: 1316-24. (Pubitemid 46869870)